295 North Bernardo Avenue
We’re Eargo. A company made up of ENT surgeons, tech geeks and dreamers, united in our belief that people should be able to hear life to the fullest. Because the world is full of great things to hear. And because, well, we really like people.
It's because we like people that we do what we do. We want the best for them, and this is our way to make sure they get it (we also like piña coladas, cuddly puppies and long walks on the beach, in case you’re wondering).
We don't believe that caring for your hearing health should come at the cost of compromising your lifestyle or appearance. That's why we’ve created devices that work superbly, are easy to use and – because of our patented Flexi Fibers – are incredibly comfortable and essentially invisible. We start with the user, the person who's going to open the Eargo box with eager anticipation, and build all of our products and experiences in ways that make them feel understood and cared for. That pays off their eager anticipation.
We feel that the best technology should be natural, not intrusive. That is should serve us, not the other way around. Through improving hearing, we want to help people live and feel better. Because, like we said before, we like people.
Ownership: Eargo’s investors include Nan Fung Life Sciences, New Enterprise Associates (NEA), Charles and Helen Schwab, Maveron, Dolby Family Ventures, Red Sea Ventures, Crosslink Capital, Peterson Ventures, Birchmere Ventures and Montage Ventures
Eargo Hearing Device - What is Eargo Hearing Aid?
16 articles with Eargo
Eargo Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Net Revenue and Preliminary Gross Systems Shipped
Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced its preliminary unaudited net revenue and preliminary gross systems shipped for the fourth quarter and year ended December 31, 2020. 1 Fourth Quarter 2020 Preliminary unaudited fourth quarter 2020 net revenue is expected to be approximately $22.2 million, compared to $10.6 million in the fourt
Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced it will present at the 39 th Annual J.P. Morgan Healthcare Conference via web cast. Christian Gormsen, Eargo’s President and Chief Executive Officer, is scheduled to present on Tuesday, January 12 th at 2:00pm Eastern Time. The live web cast of Eargo’s presentation, along with accompanying slides, c
Eargo Ranks First for Best Company Culture in Comparably AwardsEargo is also named to “Best Company for Women” and “Best CEOs” list
Eargo, Inc. a medical device company on a mission to improve the quality of life for people with hearing loss, announced that it has won the Comparably Award for “Best Company Culture” in the small business category.
Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today reported its financial results for the third quarter ended September 30, 2020.
Eargo Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 19, 2020.
Eargo, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Eargo, Inc. announced the closing of its initial public offering of 9,029,629 shares of its common stock at a public offering price of $18.00 per share, which includes 1,177,777 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Eargo, of approximately $162.5 million.
Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of $18.00 per share. In connection with the offering, Eargo has granted the underwriters a 30-day option to purchase up to an additional 1,177,777 shares of common stock at the initial public offering
Award Winning Hearing Loss Solution with Telecare Consultation & Support Sees Accelerated Consumer Demand
Eargo, a medical device company on a mission to improve the quality of life of people with hearing loss, announced that CEO Christian Gormsen has won two 2020 Comparably Awards for the categories of "Best CEOs for Diversity" and "Best CEOs for Women."
Eargo Doubles Commitment From $500,000 to $1,000,000 in Value for Healthcare Professionals and Their Families in Need of Hearing Aids
The medical device company is also offering anyone free remote hearing checks and consultations, a limited-time discount, special financing and waived return fees
Eargo Dials Up Service & Support For All Those With Hearing Loss During Coronavirus (COVID-19) Emergency
Direct-to-consumer company to provide free, remote access to licensed hearing professionals in addition to a number of offerings to ensure those with hearing challenges can receive the help they need from the comfort of their own home by calling 1-800-885-HEAR [20-March-2020] SAN JOSE, Calif. , March 20, 2020 /PRNewswire/ -- In light of the temporary closure of hearin
Eargo launches free, online hearing check in honor of World Health Organization's global observance
Virtually invisible, fourth generation device allows for greater personalization through mobile app and licensed hearing professionals
Award-winning health tech company secures investment for further product innovation, increased awareness and accelerated expansion
Eargo today announced the launch of Eargo Max, their best hearing aid yet.
10/20/2017The new investment was led by Nan Fung Life Sciences and also included investments from New Enterprise Associates NEA, Charles and Helen Schwab, and Maveron.